Abstract
Proteosome inhibitors (PI) are standard therapies for relapsed and/or refractory multiple myeloma (RRMM). Carfilzomib (CAR), an irreversible PI, is associated with greater risk of cardiovascular adverse events (CVAE) compared to bortezomib (BOR), a reversible PI. Whether PIs induce changes in
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have